Today, WebMD released In Their Own Words: Moving Beyond Migraine with Robin Roberts, a new five-part video series that sheds light on the debilitating nature of migraine and the impact it has on all aspects of a sufferer’s personal and professional life.
To learn more about treatments and the individuals featured in In Their Own Words: Moving Beyond Migraine with Robin Roberts, visit: to www.webmd.com/insidemigraines.
Moving Beyond Migraine follows the lives of Jennifer, a public school administrator who has lived with intense migraine headaches for over 20 years; Kate, a 20-year-old college student with debilitating migraines that have run in her family for generations; Melanie, whose intense migraine condition has altered the dynamics of her nine year marriage; and Lynn, who after suffering from migraine for 50 years, shares how a clinical trial for a new treatment called CGRP targeted therapy is finally providing her with some relief.
To view the multimedia release go to:
https://www.multivu.com/players/English/7579759-robin-roberts-moving-beyond-migraine/
As brain health becomes an ever greater concern for people of all ages, the nation’s largest senior living provider is now guiding its residents on developing and putting into practice personalized brain health plans. Brookdale devised the new resident program with the help of a neuropsychologist specializing in brain health. The company is putting it into place at its independent and assisted living communities across the country.
Through the new initiative, Brookdale’s residents will be offered a four-session course that explains key factors in brain health through classroom learning and hands-on activities. Each participant will be guided on creating an individual brain health plan to use on a daily basis. The course was developed with the assistance of Dr. Paul Nussbaum, who is Board Certified in clinical and geropsychology with a specialty in neuropsychology. An adjunct professor of neurological surgery at the University of Pittsburgh, he is the author of “Save Your Brain.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7722157-brookdale-brain-health/
Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its presence at the American Association for Clinical Chemistry (AACC) 2016 Clinical Lab Expo today by featuring several next-generation diagnostic testing platforms and a new virtual reality experience that gives attendees an “under the hood” look at a lab of the future and an innovative concept Roche calls the “Roche connected lab.”
The virtual reality theater will enable attendees to view samples moving through a virtual lab equipped with various configurations of Roche automation, chemistry/immunoassay platforms and molecular diagnostics systems, as well as connections to third-party platforms. The actual Roche systems that are part of the connected lab concept will also be on display in the booth.
To view the multimedia release go to:
http://www.multivu.com/players/English/7889151-roche-aacc-2016/
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.
AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/
Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen ovale (PFO) can prevent recurrent ischemic strokes, W. L. Gore & Associates, Inc. (Gore) has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its GORE® CARDIOFORM Septal Occluder. The device, already approved for closure of atrial septal defects (ASDs) up to 17 mm, is now also approved for the closure of PFO to reduce the risk of recurrent ischemic stroke in certain patients.*
To view the multimedia release go to:
https://www.multivu.com/players/English/8301551-gore-cardioform-septal-occluder-fda-approval/
The full set of data from EUCLID, the largest ever prevalence study of Clostridium difficile infection (CDI) across Europe, were presented today at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Data from 482 European hospitals reveal that in a single day, an average of 109 cases of CDI are missed due to a lack of clinical suspicion or inadequate laboratory testing, potentially leading to more than 39,000 missed cases in Europe each year.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400524-EUCLID-clostridium-difficile-infection
A recently published scientific study from Lund University by lead researcher Charlotte Erlanson-Albertsson, MD, PhD found that subjects who were trying to lose weight and used the patented spinach extract Appethyl on a daily basis lost 43 percent more weight compared to those ingesting a placebo.
In this clinical trial, overweight women were given either a daily five gram dose of Appethyl or a control drink immediately before breakfast. Researchers found that the weight of the women ingesting Appethyl decreased significantly at 43 percent more than subjects ingesting the control drink.
This is one of three studies that also compared the effects of Appethyl after 90 days with those found after the first dose and found no decline of effects, indicating that Appethyl takes effect after the first dose and is just as effective after long-term use. One study showed that Appethyl reduced hunger by 25 percent four hours after consumption, in addition to reducing thoughts about food by 33 percent.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7426951-appethyl-spinach-extract/
Soy consumption is up 14 percent since 2011,26 yet confusion lingers over soy’s role in everything from human health to food production. To clear up misperceptions, the United Soybean Board (USB) busts five common soy myths with science-backed facts on SoyConnection.com/soy-wisdom.
1) Eating soy does not increase breast cancer risk.
Clinical studies show soy isoflavone exposure does not adversely affect breast tissue as assessed by markers of breast cancer risk, such as breast cell proliferation.1–7 The American Institute for Cancer Research and the American Cancer Society say that women who have been diagnosed with breast cancer can safely consume soyfoods. In fact, the World Cancer Research Fund International has identified a link between soy consumption and an improved survival of breast cancer patients.8-9
“Not only does evidence indicate soyfoods may benefit women with breast cancer, but consuming soy when young helps prevent the onset of this disease later in life27-30,” stated Mark Messina, Ph.D., who has dedicated the past 30 years to understanding the health effects of soyfoods.
To view the multimedia release go to:
http://www.multivu.com/players/English/7877951-united-soybean-board-top-soy-myths/
Let’s Win, an initiative supported by the Lustgarten Foundation, launched the Let’s Win! Pancreatic Cancer Survivors video series Friday, January 19, 2018, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The new online video series, featuring long-term pancreatic cancer survivors of all ages and diverse backgrounds, has been created to show pancreatic cancer patients and their families that people do survive this disease. The survivors have responded exceptionally well to pancreatic cancer therapy that incorporates clinical trials and treatments that go beyond traditional protocols.
When patients are first diagnosed with pancreatic cancer, they often turn to the internet, only to find devastating and frightening statistics about the disease. “Our goal is to provide hope and inspiration to patients and their families,” says Cindy Gavin, founding executive director of Let’s Win. “We are so grateful for the incredible vision of one special patient and the generosity of The Flora Family Foundation for their support of this incredible initiative.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213752-lets-win-pancreatic-cancer-survivor-video-series/
After only 16 weeks of existence, foetuses hear and respond to music as long as it is emitted from their mother’s vagina. Foetuses respond to this stimulus by opening their mouths and pulling their tongues out as far as possible, making vocalisation movements – prior to the acquisition of language.
This is the main conclusion of the study conducted by the team of Institut Marquès, which boasts the collaboration of Alberto Prats, Professor of Anatomy and Human Embryology of the Faculty of Medicine of the University of Barcelona.
The study, entitled “Foetal facial expression in response to intravaginal music emission”, is published this week in the journal Ultrasound of the British Medical Ultrasound Society (BMUS).
According to Dr. Marisa López-Teijón, the Head of Assisted Reproduction at Institut Marquès and the principal researcher and author of the clinical study: “We have discovered that the formula for foetuses to hear like us is to emit music from the mother’s vagina. They barely hear the sound that reaches them through their mother’s abdomen: the soft tissues of the abdomen and the inside of the mother’s body absorb the soundwaves”.
To view the multimedia release go to:
http://www.multivu.com/players/English/7647351-how-foetuses-hear-musical-stimuli/
Online Learning Guideline process.
ACRI is the only institute to incorporate activity based learning methodology. Our students are placed in highly reputed firms and have been recognized for their extensive knowledge in the field of Clinical Research
Reach us :
acriindia.com/about-acri
